CASTLE ROCK, CO--(Marketwire - December 10, 2008) - AspenBio Pharma, Inc. (NASDAQ: APPY), an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for humans and animals, reported its FDA 510(k) clinical trial for AppyScore™, the world’s first blood-based diagnostic test for human appendicitis, has reached the 800 patient (study “subjects”) target and thereby has officially concluded enrollment in the study.
